secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2023-01-12T23:59:59+00:00
Accession:  0001563665-23-000004
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage CEO David Green made permanent; new agreement includes $300k salary, stock options
--------------------------------------------------------------------------------

- Interim tag removed; David Green named permanent CEO effective January 11, 2023.
- Annual base salary set at $300,000; cash incentive up to 100% of base salary.
- Initial stock option grants: $200k Black-Scholes value (monthly vesting over 12 months); fully vested option for $200k; LTI grant of 6% of outstanding shares (36-month vesting).
- Severance: $300,000 cash plus $200k Black-Scholes option if terminated without cause or for good reason.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000156366523000004/0001563665-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000156366523000004/tmb-20230111x8k.htm
  HTML page:      https://secwatch.observer/filing/0001563665-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer